CTC (Chicago Trading Company)’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-42,000
Closed -$1.75M – 231
2024
Q4
$1.75M Buy
42,000
+41,451
+7,550% +$1.98M ﹤0.01% 220
2024
Q3
$3.67M Sell
549
-716
-57% -$65.7K ﹤0.01% 200
2024
Q2
$15M Sell
1,265
-1,057
-46% -$134K 0.01% 165
2024
Q1
$24.7M Sell
2,322
-676
-23% -$68.1K 0.01% 162
2023
Q4
$29.8M Buy
2,998
+377
+14% +$31.7K 0.02% 170
2023
Q3
$27.1M Sell
2,621
-1,905
-42% -$212K 0.02% 162
2023
Q2
$55M Sell
4,526
-425
-9% -$56.7K 0.03% 134
2023
Q1
$73M Buy
4,951
+4,229
+586% +$698K 0.04% 107
2022
Q4
$130K Sell
722
-16
-2% -$2.62K 0.1% 51
2022
Q3
$87.2K Sell
738
-347
-32% -$52.7K 0.05% 84
2022
Q2
$155K Buy
1,085
+119
+12% +$17K 0.09% 49
2022
Q1
$166K Buy
966
+124
+15% +$20.9K 0.07% 63
2021
Q4
$214K Buy
842
+268
+47% +$78.4K 0.09% 53
2021
Q3
$221K Buy
+574
New +$212K 0.11% 50

Other funds holding MRNA

CTC (Chicago Trading Company)'s MRNA Position: Q1 2025 in Review

CTC (Chicago Trading Company) sold out of Moderna (MRNA) in Q1 2025, closing a stake of 24,266 shares — an estimated $1.01M sold.

CTC (Chicago Trading Company) first reported a position in MRNA in Q3 2021 and held it in 8 quarters. The position peaked at $9.52M in Q2 2023. 696 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • CTC (Chicago Trading Company) reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • CTC (Chicago Trading Company) sold 24,266 Moderna shares in Q1 2025, an estimated $1.01M.
  • CTC (Chicago Trading Company) first reported a position in Moderna in Q3 2021 and held it in 8 quarters.
  • CTC (Chicago Trading Company)'s Moderna position peaked at $9.52M in Q2 2023.
  • 696 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on CTC (Chicago Trading Company)'s 13F filing for Q1 2025, filed 16 May 2025.